References of "Colin, Claude"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailValidation de la technique de biopsie du ganglion sentinelle dans le cancer du sein
Bleret, Valerie ULg; Lifrange, Eric ULg; Ghuysen, Vincent ULg et al

in Revue Médicale de Liège (2008), 63(1), 37-42

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by ... [more ▼]

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by the radio colloid method in a consecutive series of 205 patients undergoing surgery for breast cancer stage T0-T2N0M0 between October 1998 and January 2007, initially in association with a complete axillary lymph node dissection (learning curve), later in an elective way. Prospective recording of the data and analysis with an average follow-up of 50 months (3 to 102 months). RESULTS: Biopsy rate of the sentinel lymph node of 90%, false negative rate of the method 2.5%, axillary recurrence rate 0%. CONCLUSION: We confirm in this series that the sentinel lymph node biopsy technique is a reliable approach in our experience for the evaluation of the axillary lymph node status in breast cancer stage T0-T2N0M0. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailInteret et limites du depistage de masse du cancer du sein par mammographie seule (mammotest)
Lifrange, Eric ULg; Bleret, Valerie ULg; Desreux, Joëlle ULg et al

in Revue Médicale de Liège (2003), 58(5), 331-7

The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of ... [more ▼]

The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of mammography screening, if any, is modest and the balance between beneficial (potentially, a 20% relative reduction in breast cancer mortality with no significant benefit on all-cause mortality) and harmful (physical and psychological morbidity related to the 15-40% missed cancers and the 80-90% false-positive diagnoses) effects is still delicate. The mammogram alone is a modest weapon. Concurrent clinical breast examination is mandatory. Women that are concerned about breast cancer should be fully informed of the potential benefits and risks of screening mammography. These women should benefit from mammography with concurrent clinical breast examination, and possible whole-breast ultrasound in heterogeneously dense and extremely dense breast patterns. [less ▲]

Detailed reference viewed: 100 (9 ULg)
Full Text
Peer Reviewed
See detailTraitement hormonal apres cancer du sein. Oui ... ou non?
Foidart, Jean-Michel ULg; Desreux, Joëlle ULg; Lifrange, Eric ULg et al

in Revue Médicale de Liège (2003), 58(2), 77-82

Clinical and experimental studies indicate that combined unique conjugated estrogens and medroxyprogesterone acetate moderately increase the risk of breast cancer in postmenopausal women. Classically ... [more ▼]

Clinical and experimental studies indicate that combined unique conjugated estrogens and medroxyprogesterone acetate moderately increase the risk of breast cancer in postmenopausal women. Classically, hormone replacement therapy is contra-indicated in women with a past history of breast cancer due to the fear of recurrence. However, these postmenopausal patients complain about hot flushes and adjuvant hormonal therapies (such as aromatase inhibitors, SERMs and Tamoxifen...) aggravate their symptoms. Observational studies and their meta-analyses do not show a deleterious effect but rather a beneficial impact of hormone replacement therapy among women with a past history of breast cancer. We summarise all these studies and their biological, clinical and epidemiological interpretations. We conclude that short term hormone replacement therapy is safe among those women requesting a replacement therapy after complete information. It is however advisable to conclude definitely only when prospective randomised trials with estradiol or tibolone (a promising alternative) will be available. Such ongoing studies will allow to conclude definitely the possible benefits and risks of hormone replacement therapy among patients with a past history of breast cancer. [less ▲]

Detailed reference viewed: 106 (4 ULg)
Full Text
Peer Reviewed
See detailPercutaneous stereotactic en bloc excision of nonpalpable breast carcinoma: a step in the direction of supraconservative surgery
Lifrange, Eric ULg; Dondelinger, Robert ULg; Foidart, Jean-Michel ULg et al

in Breast (Edinburgh, Scotland ) (2002), 11(6), 501-508

Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the ... [more ▼]

Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the potential of the ABBI method in locoregional management of a consecutive series of patients with nonpalpable mammographically detected breast carcinomas. Sixty-one consecutive patients underwent an ABBI procedure as a first step before possible surgery for nonpalpable breast lesions that would in any case require complete excision. For the 27 patients in whom the ABBI biopsy revealed malignancy further surgery was recommended, including re-excision of the biopsy site and axillary dissection in cases of infiltrating carcinoma. We calculated the probabilities that the ABBI specimen would have tumor-free margins and that a definitely complete excision had been achieved as a function of the mammographic or pathological diameter of the cancer. For cancer with a pathological diameter less than 10 mm, measured on the ABBI specimen, the probability (92%) of obtaining complete resection was significantly better than for larger lesions (P = 0.01, Fisher's exact test). Although the therapeutic perspectives for the ABBI method are limited at present, we suggest that this approach is a first step in the direction of a surgical strategy that is better adapted to the pathological characteristics peculiar to these small tumors, whose incidence is increasing. (C) 2002 Elsevier Science Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 60 (11 ULg)
Full Text
Peer Reviewed
See detailStereotactic breast biopsy with an 8-gauge, directional, vacuum-assisted probe: initial experience
Lifrange, Eric ULg; Dondelinger, Robert ULg; Quatresooz, Pascale ULg et al

in European Radiology (2002), 12(9), 2180-2187

This study was prospectively conducted to assess the feasibility, safety and accuracy of an 8-G directional vacuum-assisted biopsy (DVAB) probe in the diagnostic management of nonpalpable breast lesions ... [more ▼]

This study was prospectively conducted to assess the feasibility, safety and accuracy of an 8-G directional vacuum-assisted biopsy (DVAB) probe in the diagnostic management of nonpalpable breast lesions (NPBL). Of 170 planned procedures which were indicated for investigation of BI-RADS category-3 to category-5 lesions, 153 were performed in 138 consecutive patients. The probe was targeted by the stereotactic unit of a prone table (United States Surgical Corporation, Norwalk, Conn.; and Lorad, Danbury, Conn.). Four to 18 (mean 8) core specimens were obtained for each lesion. In case of complete removal of the lesion, a localizing clip was deployed at the biopsy site. Adequate material for histopathologic examination was obtained in all cases (100%). Four of 138 (3%) patients experienced mild hematomas. We observed 15 of 39 failures (38%) to place the localizing clips. Thirteen of 153 (8%) procedures were inconclusive and required reintervention. Following DVAB, 42 of 138 (30%) patients underwent surgery. Subject to incomplete follow-up of the entire cohort, we observed no false-positive and one false-negative diagnosis. These preliminary results suggest that DVAB using an 8-G probe are feasible, safe and accurate. In our experience, clip placement was problematic. It is probable that increasing the dimensions of DVAB will only be relevant in a limited number of clinical situations, primarily the desire to obtain complete radiologic resections of the target abnormality. [less ▲]

Detailed reference viewed: 23 (5 ULg)
Full Text
Peer Reviewed
See detailEn Bloc Excision of Nonpalpable Breast Lesions Using the Advanced Breast Biopsy Instrumentation System: An Alternative to Needle Guided Surgery?
Lifrange, Eric ULg; Dondelinger, R. F.; Fridman, Viviana ULg et al

in European Radiology (2001), 11(5), 796-801

This study was prospectively conducted to evaluate the clinical potential of the advanced breast biopsy instrumentation (ABBI) system as an alternative to needle localization and open surgery in the ... [more ▼]

This study was prospectively conducted to evaluate the clinical potential of the advanced breast biopsy instrumentation (ABBI) system as an alternative to needle localization and open surgery in the management of nonpalpable breast lesions (NPBL). One hundred and eighty-six consecutive patients were referred for management of NPBL. Thirty-six underwent an ABBI procedure, offered as a first step before possible surgery for lesions which would in any case have required complete excision. The 18 patients with a malignant ABBI biopsy underwent re-excision of the biopsy site and axillary dissection was carried out in cases of infiltrating carcinoma. The other 150 patients underwent image-guided needle biopsy. Following these procedures, 60/150 (40%) patients underwent needle-guided surgery. Finally, 96/186 (51%) patients required complete excision. A total of 43 benign lesions and 53 carcinomas were confirmed. Thirty-six out of 96 (38%) excisions were obtained with the ABBI system; 17/43 (40%) benign lesions and 11/53 (21%) carcinomas were completely removed with the ABBI system. Out of 9 malignant specimens with a pathological size less than 10 mm, 5/9 (55%) had tumor-free margins and in 8/9 (89%) no residual disease was found at re-excision. The preliminary results of this study suggest that, in selected cases, en bloc excision using the ABBI procedure could be an alternative to conventional surgery. [less ▲]

Detailed reference viewed: 4 (1 ULg)
Peer Reviewed
See detailLa chirurgie mammaire supraconservatrice
Lifrange, Eric ULg; Colin, Claude ULg

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (2000), 29(3), 285-7

Currently, 30% of the breast biopsies are performed for patients with nonpalpable lesions. The surgical management of these lesions had to evolve to a better three-dimensional targeting and a reduction of ... [more ▼]

Currently, 30% of the breast biopsies are performed for patients with nonpalpable lesions. The surgical management of these lesions had to evolve to a better three-dimensional targeting and a reduction of the tissue traumatism. The ABBI procedure allows the percutaneous one bloc excision of suspicious mammographically detected lesions with a diameter of less than 2cm. We prospectively evaluated this procedure as a therapeutic tool. Of the 10 malignant lesions with a pathologic size <10mm, 9 (90%) were completely resected with the ABBI device (no residual disease at re-excision of the biopsy site). The results of this preliminary study suggest a potential therapeutic role of the ABBI procedure in the therapeutic arsenal against mammary lesions. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailLes faces cachées du cancer du sein: modalites du suivi des hyperplasies et des cancers in situ
Lifrange, Eric ULg; Colin, Claude ULg

in Contraception, Fertilite, Sexualité (1992) (1999), 27(5), 364-7

After the diagnosis of breast epithelial hyperplasia or carcinoma in situ, the clinical follow-up must take into account several parameters. First, the adequacy of the diagnostic and the therapeutic ... [more ▼]

After the diagnosis of breast epithelial hyperplasia or carcinoma in situ, the clinical follow-up must take into account several parameters. First, the adequacy of the diagnostic and the therapeutic approach is to be evaluated. Second, the patient must be informed of her risk of subsequent breast cancer. In such a protocol, one can recommend a program of close follow-up in an attempt at early detection. An annual clinical examination combined with a mammographic and a sonographic exam is considered as the method of choice. In between annual check-ups, clinical exam is encouraged. The potential benefits of magnetic-resonance imaging in these circumstances is currently evaluated. In rare instances, the absolute risk of breast cancer is so high that a prophylactic mastectomy can be considered. [less ▲]

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailA propos des prothèses mammaires. L'examen senologique conventionnel
Lifrange, Eric ULg; Colin, Claude ULg

in Revue Médicale de Liège (1998), 53(12), 746-9

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailA propos de la prévention du cancer du sein par le tamoxifene
Foidart, Jean-Michel ULg; Colin, Claude ULg; Lifrange, Eric ULg

in Revue Médicale de Liège (1998), 53(4), 225-6

Detailed reference viewed: 17 (7 ULg)
Peer Reviewed
See detailVers une chirurgie "supraconservatrice" des lésions mammaires infracliniques?
Lifrange, Eric ULg; Colin, Claude ULg

in Revue Médicale de Liège (1997), 52(2), 72-6

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailStereotaxic Needle-Core Biopsy and Fine-Needle Aspiration Biopsy in the Diagnosis of Nonpalpable Breast Lesions: Controversies and Future Prospects
Lifrange, Eric ULg; Kridelka, Frédéric ULg; Colin, Claude ULg

in European Journal of Radiology (1997), 24(1), 39-47

OBJECTIVE: To determine the advantages and limitations of a combined stereotaxic fine-needle aspiration biopsy and needle-core biopsy in the diagnosis of 353 nonpalpable breast lesions with special ... [more ▼]

OBJECTIVE: To determine the advantages and limitations of a combined stereotaxic fine-needle aspiration biopsy and needle-core biopsy in the diagnosis of 353 nonpalpable breast lesions with special attention given to the collection of follow-up data. METHODS AND MATERIAL: 353 nonpalpable breast lesions underwent 'one pass' stereotaxic fine-needle aspiration (21 gauge needle) and needle-core biopsy (18 gauge needle) at our institution from January 1990 to October 1993. Stereotaxic biopsies were carried out by means of an 'add-on unit'. Surgical biopsy was usually recommended for highly suspicious radiologic patterns and/or needle biopsy reports classified as atypical or malignant. In all other cases mammographic follow-up was advised at 6 months and then annually for 3 years. The data were collected retrospectively during September 1995 (theoretical average follow-up of greater than 3 years). RESULTS: Following the combined needle biopsy technique procedure, surgery was recommended for 83 lesions. Fifty-four cancers were associated to these suspicious lesions. Because of changing radiological or clinical pattern during follow-up (mean follow-up: 22 months), 11 cancers were detected among the 270 lesions initially considered not to need surgery. Forty-three percent of the 65 malignant lesions were initially read as having less than highly suspicious mammographic features. There was no significant difference between the sensitivity and the specificity of one pass fine-needle aspiration biopsy (57% and 96% respectively) and needle-core biopsy (60% and 97% respectively), but noncontributive samples were not included in the false negative diagnoses and atypical samples were included in the true positive diagnoses. Of the 11 missed cancers, nine were manifested initially by clusters of calcifications. Our diagnostic approach was significantly less sensitive (P = 0.006) and less specific (P = 0.032) in cases of clusters of calcifications (31% false negative diagnoses) than in cases of soft-tissue masses (5.5% false negative diagnoses). In this study, an average delay in diagnoses of 22 months was responsible for a significantly increased percentage of axillary node positive invasive cancer (P < 0.001) and six of the 11 missed cancers were palpable at the time of the delayed diagnosis. For the nine cancers initially manifested by calcifications, the 22 months delay in diagnosis was responsible for a nonsignificant increase of microinvasive type at the expense of carcinoma in situ. CONCLUSION: Our enthusiasm with the sensitivity of this double stereotaxic needle sampling has been tempered by the results of this reanalysis in the light of a mean theoretical follow-up of three years. Our diagnostic approach was adequate in the presence of soft-tissue masses but not valid in the presence of clustered calcifications. When dealing with calcifications, multiple samplings must be done in order to improve the sensitivity of the diagnosis. Furthermore, this study does not favour the theory that the majority of mammographically detected cancers are indolent and highlights the poor sensitivity of the mammographic follow-up of nonpalpable lesions. [less ▲]

Detailed reference viewed: 17 (4 ULg)
Full Text
Peer Reviewed
See detailLe tamoxifene dans le traitement du cancer du sein
Charlier, Corinne ULg; Colin, Claude ULg; Merville, Marie-Paule ULg et al

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (1994), 23(7), 751-6

Tamoxifen is the most often prescribed non steroidal antioestrogenic agent in the world for breast cancer. Worldwide collaboration. has centralized the results, of different trials throughout the world on ... [more ▼]

Tamoxifen is the most often prescribed non steroidal antioestrogenic agent in the world for breast cancer. Worldwide collaboration. has centralized the results, of different trials throughout the world on oral adjuvant therapy in the early stages of breast cancer. A significative regression of the tumour was observed in most cases. Moreover, recent epidemiological studies suggest that tamoxifen could prevent new contralateral primary tumours. The risk of the disease should thus be reduced by the prophylactic use of antioestrogens such as tamoxifen. Investigations using a variety of models have evaluated the effect of tamoxifen on tumour promotion and cell growth. Tamoxifen-induced growth inhibition is associated with major changes in biochemical events in cultured human breast cancer cells including cell proliferation or growth factor production. Growth inhibition of oestrogen-responsive human breast cancer cells is associated with an induced secretion of autoinhibitory polypeptides (TGF beta) and an antagonistic effect on the synthesis of proliferative proteins (TGF alpha,...). The first step in the mechanism of action of the drug is binding of tamoxifen to the oestrogen receptors. Development of resistance to tamoxifen treatment is a great problem in treatment of breast cancer patients and the mechanism of resistance will require further study: under the influence of the drug, tumours could become remodelled as selected subpopulations emerge resistant-tamoxifen. The fact that some breast cancers which are oestrogen receptor-negative respond to antioestrogen suggests that parallel but separate pathways for oestrogen and antioestrogen action may exist. This paper summarizes the results of the most recent studies concerning this promising drug. [less ▲]

Detailed reference viewed: 208 (11 ULg)
Full Text
Peer Reviewed
See detailLe tamoxifene comme premier traitement du cancer du sein chez la femme âgée: un recul de 10 ans
Colin, Claude ULg; Lifrange, Eric ULg; Genicot, F. et al

in Revue Médicale de Liège (1990), 45(11), 533-8

Cinquante-six patientes, âgées de plus de 70 ans, ont été traitées par tamoxifène pour cancer mammaire T1 à T4. Un délai de 3 à 6 mois est nécessaire pour obtenir une régression de l'opacité tumorale dans ... [more ▼]

Cinquante-six patientes, âgées de plus de 70 ans, ont été traitées par tamoxifène pour cancer mammaire T1 à T4. Un délai de 3 à 6 mois est nécessaire pour obtenir une régression de l'opacité tumorale dans 46,4% des cas, une stabilisation dans 30,4% et une augmentation dans 23,2%. Le type de réponse semble indépendant du stade initial de la tumeur. La survie globale à 10 ans n'est pas différente de cette des patientes de même âge qui avaient préféré recourir au traitement loco-régional classique. Par contre, en cas de régression tumorale, la durée de la survie est nettement plus longue et est comparable à celle d'une population témoin de même âge. Les récidives locales sont fréquentes. Elle sont de moins bon pronostic si elles surviennent au cours des trois premières années du traitement. La véritable cause du décès est souvent difficile à préciser chez ces patientes. Une relation directe avec le cancer mammaire n'est observée que dans la moitié des cas. [less ▲]

Detailed reference viewed: 85 (10 ULg)
Peer Reviewed
See detailPossible Role of Human Natural Anti-Gal Antibodies in the Natural Antitumor Defense System
Castronovo, Vincenzo ULg; Colin, Claude ULg; Parent, B. et al

in Journal of the National Cancer Institute (1989), 81(3), 212-6

Expression of Gal alpha 1-3Gal cell surface residues has been correlated with the metastatic potential of murine tumor cells. We report that Gal alpha 1-3Gal residues are expressed at the cell surface of ... [more ▼]

Expression of Gal alpha 1-3Gal cell surface residues has been correlated with the metastatic potential of murine tumor cells. We report that Gal alpha 1-3Gal residues are expressed at the cell surface of malignant human cancer cells, including four cell lines and 50% of the malignant breast specimens obtained by aspiration biopsy. In contrast, all benign breast biopsies and normal cells were Gal alpha 1-3Gal negative. Affinity-purified anti-alpha-galactosyl IgG (anti-Gal) antibody, which specifically recognizes Gal alpha 1-3Gal residues, significantly inhibited cell attachment in two in vitro assays thought to indicate tumor cell extravasation of the circulatory system during the metastatic process: attachment to perfused human umbilical vein endothelium, and attachment to isolated laminin. Since anti-Gal antibody is a natural component of all human sera, we propose that it may be part of the natural antitumor defense system in humans. [less ▲]

Detailed reference viewed: 15 (1 ULg)